BCL2 and B-cell chronic lymphocytic leukemia: CLL is often managed with Bruton tyrosine kinase inhibitors (BTKi) such as ibrutinib and acalabrutinib or inhibitors of B-cell lymphoma-2 (BCL-2) such as venetoclax.